A Phase III Randomized Trial of Adding Vincristine-topotecan- cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma

ID Number 80-0066-00074

Principal Investigator(s)
Birte Wistinghausen

Department(s) or Division(s)
Hematology/Oncology

Description

The purpose of this study is to find if adding the drug combination VTC (vincristine/ topotecan/ cyclophosphamide) to the standard five-drug chemotherapy (cancer fighting medicine)  for Ewing sarcoma will get rid of the cancer better than the standard five-drug chemotherapy by itself
You/ your child may qualify to take part in this research study because because you/your child have been diagnosed with a type of tumor called Ewing sarcoma that is localized. Ewing sarcoma is a type of tumor that occurs in the bones or the soft tissues around the bones. A localized tumor is one that has not spread to any other places in the body.



Contact Information
Katrina Watson
(212) 241-6906


Recruiting Patients: Yes